A group from Siemens Healthcare ($SI) and Saarland University in Germany says they've developed a blood test that could identify patients with Alzheimer's disease and rule out the affliction in others. Their test focused on a panel of 12 miRNAs, which appeared in different levels in Alzheimer's patients versus healthy controls. Subsequently, the concept worked again in a larger patient sample and surpassed the 90% level in accuracy, sensitivity and specificity. Details are published in the journal Genome Biology. Item | Journal abstract